A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

March 31, 2033

Study Completion Date

March 31, 2033

Conditions
Growth Hormone Deficiency
Interventions
DRUG

No intervention

No intervention

Trial Locations (23)

11042

RECRUITING

Ascendis Investigational Site, New Hyde Park

20010

RECRUITING

Ascendis Investigational Site, Washington D.C.

23505

RECRUITING

Ascendis Investigational Site, Norfolk

29203

RECRUITING

Ascendis Investigational Site, Columbia

30350

RECRUITING

Ascendis Investigational Site, Sandy Springs

32806

RECRUITING

Ascendis Investigational Site, Orlando

32827

RECRUITING

Ascendis Investigational Site, Orlando

33612

RECRUITING

Ascendis Investigational Site, Tampa

40202

RECRUITING

Ascendis Investigational Site, Louisville

46202

RECRUITING

Ascendis Investigational Site, Indianapolis

52242

RECRUITING

Ascendis Investigational Site, Iowa City

55455

RECRUITING

Ascendis Investigational Site, Minneapolis

79938

RECRUITING

Ascendis Investigational Site, El Paso

80112

RECRUITING

Ascendis Pharma Investigational Site, Centennial

83712

RECRUITING

Ascendis Investigational Site, Boise

85054

RECRUITING

Ascendis Investigational Site, Phoenix

89113

RECRUITING

Ascendis Investigational Site, Las Vegas

94143

RECRUITING

Ascendis Investigational Site, San Francisco

95821

RECRUITING

Ascendis Investigational Site, Sacramento

97239

RECRUITING

Ascendis Investigational Site, Portland

98105

RECRUITING

Ascendis Investigational Site, Seattle

03756

RECRUITING

Ascendis Investigational Site, Lebanon

07960

RECRUITING

Ascendis Investigational Site, Morristown

All Listed Sponsors
lead

Ascendis Pharma Endocrinology Division A/S

INDUSTRY